Phathom Pharmaceuticals (PHAT) stock is surging 5.79% in pre-market trading on Friday, following the release of its third-quarter 2025 earnings report and a positive analyst update. The pharmaceutical company's shares are gaining momentum as investors react to the latest financial results and revised market outlook.

The company's Q3 earnings release, while details are limited, suggests strong growth for Phathom Pharmaceuticals in the third quarter of 2025. This positive performance has caught the attention of Wall Street analysts, with H.C. Wainwright raising its target price for PHAT stock from $20 to $26, signaling increased confidence in the company's future prospects.

Adding to the bullish sentiment, HC Wainwright & Co. has maintained its Buy rating on Phathom Pharmaceuticals. This combination of strong quarterly results and analyst optimism appears to be driving the significant pre-market rally, as investors position themselves ahead of the regular trading session in anticipation of potential further gains.